Supernus to acquire CNS Portfolio from US WorldMeds for $530m
Supernus will acquire APOKYN, MYOBLOC, and XADAGO, along with Apomorphine Infusion Pump, which is currently under late-stage development
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
30 Apr 20
Supernus will acquire APOKYN, MYOBLOC, and XADAGO, along with Apomorphine Infusion Pump, which is currently under late-stage development
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
29 Apr 20
FIREFISH Part 2 study met its primary endpoint by demonstrating a significant increase in motor milestones in infants…
29 Apr 20
Cosentyx is indicated for patients with non-radiographic axial spondyloarthritis (nr-axSpA), a part of the axial spondyloarthritis (axSpA) disease…
28 Apr 20
Moderna’s new mRNA-1273 is an mRNA vaccine that works against SARS-CoV-2 encoding for a prefusion stabilized form of…
28 Apr 20
Regeneron and Sanofi have amended the clinical trial to continue enrolling only critical patients to receive Kevzara 400mg…
Analysts are torn on the potential of remdesivir as a Covid-19 vaccine after Gilead Sciences halted a trial…
27 Apr 20
Lynparza has been granted priority review by the US Food and Drug Administration for patients with HRRm mCRPC
24 Apr 20
Farxiga is an oral, once-daily sodium-glucose cotransporter 2 (SGLT2) inhibitor used for the treatment of insufficiently controlled T2D
24 Apr 20
ChAdOx1 nCoV-19 has been developed through genetically modifying ChAdOx1 virus, a weakened version of common cold virus
The experience of adapting to new challenges for the cold chain may well prove vital when pharmaceutical companies…
FacilitiesPharmaceuticals and MedicinesClinical supplies and logistics